BR112012024683A2 - preparado sólido facilmente dosável - Google Patents

preparado sólido facilmente dosável

Info

Publication number
BR112012024683A2
BR112012024683A2 BR112012024683A BR112012024683A BR112012024683A2 BR 112012024683 A2 BR112012024683 A2 BR 112012024683A2 BR 112012024683 A BR112012024683 A BR 112012024683A BR 112012024683 A BR112012024683 A BR 112012024683A BR 112012024683 A2 BR112012024683 A2 BR 112012024683A2
Authority
BR
Brazil
Prior art keywords
sodium alginate
thickening agent
coating composition
solid prepared
group
Prior art date
Application number
BR112012024683A
Other languages
English (en)
Other versions
BR112012024683B1 (pt
Inventor
Kuniomi Warabino
Yumio Kudou
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of BR112012024683A2 publication Critical patent/BR112012024683A2/pt
Publication of BR112012024683B1 publication Critical patent/BR112012024683B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

preparado sólido facilmente dosável. é o objeto proporcionar uma composição do revestimento, que é usada para um preparado oralmente administrado, a propriedade de administração que tenha sido melhorada e/ou um preparado facilmente administrável, que não afeta a propriedade de dissolução. o objeto acima referido pode ser conseguido usando uma composição do revestimento compreendendo um primeiro agente espessante selecionado a partir do grupo consistindo de um polímero carboxivinil e alginato de sódio, um composto de metal polivalente e pelo menos um tipo de um segundo agente espessante selecionado a partir do grupo consistindo de goma xantana, goma guar e o alginato de sódio, com a resslava de que quando o primeiro agente espessante é o alginato de sódio, o segundo agente espessante não pode ser o alginato de sódio, ou usando uma composição do revestimento compreendendo, como agentes espessantes a hidroxipropilmetilcelulose e o açúcar ou álcool de açúcar possuindo uma solubilidade a 20 °c de 30 ou mais.
BR112012024683-6A 2010-03-31 2011-03-30 Composição oral BR112012024683B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010-082759 2010-03-31
JP2010082759 2010-03-31
PCT/JP2011/058133 WO2011125798A1 (ja) 2010-03-31 2011-03-30 易服用性固形製剤

Publications (2)

Publication Number Publication Date
BR112012024683A2 true BR112012024683A2 (pt) 2016-06-07
BR112012024683B1 BR112012024683B1 (pt) 2019-09-24

Family

ID=44762737

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012024683-6A BR112012024683B1 (pt) 2010-03-31 2011-03-30 Composição oral

Country Status (12)

Country Link
US (2) US20120082723A1 (pt)
EP (1) EP2561892B1 (pt)
JP (2) JP5426018B2 (pt)
KR (1) KR101767288B1 (pt)
CN (2) CN104258408B (pt)
AU (1) AU2011237122B2 (pt)
BR (1) BR112012024683B1 (pt)
CA (1) CA2788732C (pt)
ES (1) ES2543108T3 (pt)
MX (1) MX2012010648A (pt)
RU (1) RU2574018C2 (pt)
WO (1) WO2011125798A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5976657B2 (ja) 2011-09-30 2016-08-24 持田製薬株式会社 易服用性固形製剤
ES2694224T3 (es) * 2012-04-24 2018-12-19 Daiichi Sankyo Company, Limited Comprimido de desintegración oral y procedimiento para producir el mismo
JP6160813B2 (ja) * 2012-04-26 2017-07-12 キョーリンリメディオ株式会社 高含量レボフロキサシン錠剤
CN103040835B (zh) * 2013-01-14 2018-06-22 常州市亚邦医药研究所有限公司 一种含有枸橼酸西地那非的药用组合物及其制备方法
WO2014136857A1 (ja) * 2013-03-08 2014-09-12 ライオン株式会社 コーティング組成物、コーティング製剤及びその製造方法
JP6282939B2 (ja) * 2014-06-05 2018-02-21 株式会社ファンケル 耐酸性錠剤
JP6418806B2 (ja) * 2014-06-19 2018-11-07 カンロ株式会社 とろみを有するキャンディの製造方法
CN106794253B (zh) * 2014-09-03 2021-02-12 狮王株式会社 包衣制剂及其制造方法
AU2015369696B2 (en) * 2014-12-23 2019-01-24 International N&H Usa, Inc. Enteric film coating compositions, method of coating, and coated forms
TWI695722B (zh) * 2015-06-29 2020-06-11 日商大賽璐股份有限公司 固態製劑之外層用組成物及含有該外層用組成物之易服用性固態製劑
KR102671429B1 (ko) 2015-09-30 2024-05-30 주식회사 다이셀 복용 용이성 고형 제제용 입자 조성물 및 상기 입자 조성물을 포함하는 복용 용이성 고형 제제
US10232045B2 (en) * 2016-08-04 2019-03-19 Bpsi Holdings Llc Easy to swallow coatings and substrates coated therewith
JP6944822B2 (ja) * 2017-06-27 2021-10-06 持田製薬株式会社 易服用性カプセル
CN111936168A (zh) * 2018-04-17 2020-11-13 株式会社大赛璐 易服用性颗粒剂及其制造方法
EP3845250B1 (en) * 2018-08-30 2022-07-06 FUJIFILM Corporation Biocompatible material
JP7317940B2 (ja) 2019-03-04 2023-07-31 沢井製薬株式会社 フィルムコーティング組成物及び固形製剤
CN116193994A (zh) 2020-07-13 2023-05-30 麒麟控股株式会社 薄膜包衣片剂

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439194A (en) * 1981-09-08 1984-03-27 Merck & Co., Inc. Water and drug delivery system for suppository use
US5536511A (en) * 1994-05-06 1996-07-16 Wm. Wrigley Jr. Company Chewing gum pellet coated with a hard coating containing erythritol and xylitol
WO1998006385A1 (de) 1996-08-15 1998-02-19 Losan Pharma Gmbh Gut schluckbare orale arzneiform
CA2290624C (en) * 1997-06-06 2006-12-05 John W. Shell Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
JPH1160472A (ja) 1997-08-18 1999-03-02 Ota Seiyaku Kk フィルムコーティング用組成物
IN186245B (pt) * 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US7223421B2 (en) * 2000-06-30 2007-05-29 Mcneil-Ppc, Inc. Teste masked pharmaceutical particles
KR100790056B1 (ko) 2000-09-06 2007-12-31 미쯔비시 웰 파마 가부시키가이샤 경구용 입제제(粒製劑)
CA2440588C (en) * 2001-03-13 2010-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
JP2002275054A (ja) * 2001-03-19 2002-09-25 Dainippon Pharmaceut Co Ltd 易服用性固形製剤
AU2002255267B2 (en) 2001-04-24 2007-12-20 Lintec Corporation An orally administered agent and an orally administered agent/supporting substrate complex
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
AU2003224358A1 (en) * 2002-05-06 2003-11-17 Ranbaxy Laboratories Limited Monocompartment osmotic controlled drug delivery system
US7169450B2 (en) * 2002-05-15 2007-01-30 Mcneil-Ppc, Inc. Enrobed core
WO2004000918A1 (en) * 2002-06-19 2003-12-31 Showa Denko K. K. Hydrous gel and production process and use of the hydrous gel
JP2005289867A (ja) * 2004-03-31 2005-10-20 Lintec Corp 経口投与剤
EP1745775B1 (en) * 2005-07-19 2008-05-28 Ethypharm Gastroretentive formulations and manufacturing process thereof.
WO2007063553A1 (en) * 2005-11-29 2007-06-07 Ideal Cures Pvt. Ltd. Aqueous film coating composition containing sodium alginate and preparation thereof
ES2547226T5 (es) * 2006-08-30 2020-06-12 Jagotec Ag Formulaciones de dosificación oral de liberación controlada que comprenden un núcleo y una o más capas de barrera
WO2008077643A1 (en) * 2006-12-22 2008-07-03 Farmaprojects, S.A. Process for the preparation of an antibacterial quinolone compound
AU2007352009B2 (en) * 2007-03-30 2013-08-01 Lintec Corporation Process for producing preparation for oral administration
AU2008305243B2 (en) * 2007-09-28 2013-09-12 Lintec Corporation Medicinal preparation for oral administration
JP2011500553A (ja) * 2007-10-10 2011-01-06 ルピン・リミテッド ５−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤
WO2009119290A1 (ja) * 2008-03-28 2009-10-01 リンテック株式会社 経口投与剤
CN101438734B (zh) * 2008-12-29 2012-12-12 贵州大学 刺梨涂膜保鲜剂制备及其低温保鲜的配套方法
AU2010228258A1 (en) * 2009-03-25 2011-09-29 Aska Pharmaceutical Co., Ltd. Solid preparation

Also Published As

Publication number Publication date
CA2788732A1 (en) 2011-10-13
BR112012024683B1 (pt) 2019-09-24
CN102858373A (zh) 2013-01-02
CA2788732C (en) 2017-08-15
CN104258408A (zh) 2015-01-07
JP5871886B2 (ja) 2016-03-01
JPWO2011125798A1 (ja) 2013-07-08
CN102858373B (zh) 2014-11-26
MX2012010648A (es) 2012-11-09
EP2561892A4 (en) 2013-09-04
KR101767288B1 (ko) 2017-08-10
EP2561892B1 (en) 2015-05-06
US20150079171A1 (en) 2015-03-19
AU2011237122B2 (en) 2014-06-12
RU2012146100A (ru) 2014-05-10
US20120082723A1 (en) 2012-04-05
CN104258408B (zh) 2017-10-03
JP5426018B2 (ja) 2014-02-26
EP2561892A1 (en) 2013-02-27
KR20130086128A (ko) 2013-07-31
ES2543108T3 (es) 2015-08-14
AU2011237122A1 (en) 2012-09-06
JP2014074039A (ja) 2014-04-24
WO2011125798A1 (ja) 2011-10-13
RU2574018C2 (ru) 2016-01-27

Similar Documents

Publication Publication Date Title
BR112012024683A2 (pt) preparado sólido facilmente dosável
BR112015008186A2 (pt) formulação de um anticorpo estável e de baixa viscosidade
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
BR112013022495A2 (pt) formulação farmacêutica aquosa de tapentadol para administração oral
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
AR088381A1 (es) Formulaciones de etanercept estabilizadas con meglumina
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
BR112013003581A2 (pt) formulação farmacêutica ou nutracêutica gastro resistente que compreende um ou mais sais do ácido algínico
BR112012033077B8 (pt) Composição farmacêutica para administração intravenosa, uso de uma composição farmacêutica, e, kit
BR112017027688A2 (pt) Composições orais que contêm éster de 17- hidroxiprogesterona e métodos relacionados
BR112014016550A2 (pt) formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma
EA201600118A1 (ru) Жидкая водная фармацевтическая композиция с консервантами, содержащая этерифицированные производные циклодекстрина
AR080242A1 (es) Composiciones veterinarias. usos.
NI201400122A (es) Agentes terapéuticos para administración subcutánea optimizados
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112014016661A8 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
BR112015031878A2 (pt) composição farmacêutica
BR112015019264A8 (pt) cápsulas para o tratamento de helicobacter pylori e seu uso".
RU2014142066A (ru) Состав с длительным высвобождением для снижения частоты мочеиспускания и способ его применения
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
BR112015001640A2 (pt) formulações e métodos de produção de formulações para uso em evacuação colônica
BR112013001462B8 (pt) Composições
RU2016129069A (ru) Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2716 DE 24-01-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.